

Supplementary material

Pelewicz-Sowa M, Kajfasz M, Maślińska M, et al. IgG4-related disease: sight-threatening orbital disease, spectacular improvement after rituximab therapy. Pol Arch Intern Med. 2023; 133: 16360. doi:10.20452/pamw.16360

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

| | Before Rituximab | After Rituximab | Reference range |
|---|------------------|-----------------|-----------------|
| Serum IgG4 concentrations, mg/dl | 1000 | 33 | <135 |
| Aspartate aminotransferase, U/l | 120 | 7 | 5-40 |
| Alanine aminotransferase, U/l | 123 | 36 | 7-56 |
| Gamma-glutamyl transpeptidase, U/l | 558 | 162 | 15-73 |
| Triglycerides, mg/dl | 316 | 183 | 50-150 |
| Total cholesterol, mg/dl | 200 | 170 | 120-200 |
| Low-density lipoprotein cholesterol, mg/dl | 297 | 60 | <55 |
| High-density lipoprotein cholesterol, mg/dl | 22 | 73 | >85 |
| Thyroid-stimulating hormone, μ U/l | 1.75 | 4.72 | 0.27-4.2 |
| Free triiodothyronine, pmol/l | 5.02 | 3.62 | 3.1-6.8 |
| Free thyroxine, pmol/l | 21.11 | 20.9 | 12.0-22.0 |
| Thyrotropin receptor antibodies, IU/l | 0.59 | 0.80 | <1.75 |
| Thyroglobulin antibodies, IU/ml | 233.1 | 14.5 | <115.0 |
| Thyroid peroxidase antibodies, IU/ml | 177.2 | 19.5 | <34.0 |
| NT- proBNP, pg/ml | 226 | 36 | <125 |
| Creatinine, mg/dl | 0.77 | 0.40 | 0.5-1.0 |
| Uric acid, mg/dl | 11.45 | 6.25 | 3.5-8.5 |

| | Before Rituximab | | After Rituximab | | Reference range |
|-------------------------|------------------|----------|-----------------|----------|-----------------|
| | Right eye | Left eye | Right eye | Left eye | |
| Transverse diameter, mm | | | | | |
| Lateral rectus muscle | 26 | 26 | 13 | 13 | <3.3 |
| Medial rectus muscle | 11 | 22 | 6.5 | 9 | <4.2 |
| Superior rectus muscle | 18 | 13 | 7 | 6 | <4.6 |
| Inferior rectus muscle | 26 | 26 | 13 | 13 | <4.8 |

Table S3 Positron emission tomography in patient with IgG4-Related Disease before and after treatment with Rituximab.

| | Before Rituximab | | After Rituximab | |
|---------------------|------------------|---------------------------------|-----------------|---------------------------------|
| | Dimensions, mm | SUV _{max} ^a | Dimensions, mm | SUV _{max} ^a |
| Extraocular muscles | Not described | 10 | Not described | 2.7 |
| Palatine tonsils | Not described | 5.7 | Not described | 7.5 |
| Lymph nodes | | | | |
| Cervical | 23x28 | 12.5 | Not described | 0 |
| Mediastinal | 15x20 | 3.7 | Not described | 0 |
| Hilar | Not described | 4.2 | Not described | 0 |
| Axillary | 37x20 | 7 | Not described | 0 |
| Abdominal | Not described | 0 | Not described | 0 |
| Pelvic | 25x12 | 5.9 | 24x13 | 1.4 |
| Liver ^b | 165 | 4.1 | 180 | 3.6 |
| Spleen ^b | 107 | 3 | 135 | 2.2 |
| Bones | Not described | 0 | Not described | 0 |

^a Measurement of uptake of fluorine-18-labeled fluorodeoxyglucose in tissue.

^b Cranial-caudal measurement.

Abbreviations: SUV_{max}, maximum standardized uptake value